Search the Newsreel

Research Analysts Issue Forecasts for BCRX Q4 Earnings

Wedge Capital Management L L P NC Acquires Shares of 380,801 BioCryst Pharmaceuticals, Inc. $BCRX

Wedge Capital Management L.L.P. NC recently purchased 380,801 shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for approximately $3.8 million, now holding 0.15% of the company. Institutional investors collectively own 85.88% of the biotechnology firm. BioCryst Pharmaceuticals reported strong quarterly earnings, beating analyst estimates with $0.30 …

Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BioCryst Pharmaceuticals (BCRX) is back in focus after raising its full year 2026 revenue …

BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. BioCryst Pharmaceuticals stock has put up a 53.0% gain over the past three years, yet the current valuation checks still lean on the …

BioCryst (BCRX) Q2 2026 Earnings Call Transcript

BioCryst Pharmaceuticals reported strong Q2 2026 results, with total revenue up 45% year-over-year to $218.3 million and ORLADEYO net revenue increasing 10% to $158.2 million. The company is transitioning to an external innovation model, closing its Birmingham research facility, and has launched its pediatric …

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

Shares of BioCryst Pharmaceuticals (BCRX) have gained 6.2% over the past four weeks to close the last trading session at $10.34, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. …

BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a 111.57% Potential Upside

BioCryst Pharmaceuticals, Inc. (BCRX) presents a significant growth opportunity in the biopharmaceutical sector, driven by its focus on rare diseases and a strong pipeline including ORLADEYO. Analysts project a substantial 111.57% potential upside with an average target price of $20.82, fueled by robust revenue …

BioCryst Pharmaceuticals (BCRX) Could Be 54% Undervalued Following Strong Earnings Guidance

BioCryst Pharmaceuticals (BCRX) is potentially 54% undervalued, with a fair value estimated at $21.30 per share against a last close of $9.84. This outlook follows a strong Q2 2026 report showing higher revenue, improved net income, and a raised full-year revenue forecast, coupled with …

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6% - What's Next?

BioCryst Pharmaceuticals (NASDAQ:BCRX) saw its stock price increase by 6% in mid-day trading following strong quarterly results, where the company exceeded EPS and revenue expectations. Analysts maintain a "Moderate Buy" consensus with an average price target of $20.60, despite varied individual ratings. Institutional investors …

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

Investors in BioCryst Pharmaceuticals, Inc. BCRX need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 18, 2026 $2 Put had some of the highest implied volatility of all equity options today. What …

BioCryst Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had approximately 411 employees worldwide as of March 2026, representing a 3.8% decline since 2023. The company is actively hiring, though job postings have decreased significantly, and its workforce is primarily concentrated in the United States. Employee sentiment is …

BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Strong-Buy at Wall Street Zen

BioCryst Pharmaceuticals (NASDAQ:BCRX) has been upgraded to a "strong-buy" rating by Wall Street Zen. The company reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, with revenue increasing 33.6% year over year. Despite a recent price target decrease from Royal Bank …

State Street Corporation (BCRX) discloses 15.2M BioCryst shares in 13G filing

State Street Corporation has disclosed a beneficial ownership of 15,191,098 shares of BioCryst Pharmaceuticals, Inc. common stock, which represents a 6% stake in the company. This disclosure was made via a Schedule 13G filing, indicating a passive investment. While State Street has shared dispositive …

How BioCryst’s Higher 2026 Revenue Guidance and Mixed Earnings Picture Will Impact BioCryst Pharmaceuticals (BCRX) Investors

BioCryst Pharmaceuticals (BCRX) reported Q2 2026 revenue of US$218.25 million and a net income of US$78.40 million, while raising its full-year 2026 revenue guidance to US$690 million to US$715 million. This positive short-term outlook, driven by ORLADEYO sales, contrasts with a six-month net loss …

BioCryst WARN filing reveals 47 jobs affected by Birmingham research center closure

BioCryst Pharmaceuticals will lay off 47 employees starting October 7, 2026, as it closes its Birmingham-area Discovery Center of Excellence. This decision is part of a strategic shift to focus on externally sourced innovation and reduce operating costs, with the company lowering its 2026 …

Wedbush Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price

BioCryst Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $20.82, Implies 131% Upside

BioCryst Pharmaceuticals, Inc.'s average 12-month price target has been lowered slightly from $21 to $20.82 by 11 analysts, with forecasts ranging from $12 to $32 per share. This new target suggests a potential upside of approximately 131% based on the Aug. 4 closing price. …

Dimensional Fund Advisors LP Has $25.61 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX

Dimensional Fund Advisors LP significantly increased its stake in BioCryst Pharmaceuticals (NASDAQ:BCRX) by 119% in the first quarter, now holding 2.69 million shares valued at $25.6 million. This move is consistent with a generally positive outlook from analysts, who have assigned a "Moderate Buy" …

RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating

RBC Capital has adjusted its price target for BioCryst Pharmaceuticals (BCRX) to $13, down from $14, while maintaining an Outperform rating on the stock. This revision comes amidst recent company news, including the discontinuation of internal drug discovery programs and a positive earnings report …

BioCryst Pharmaceuticals (BCRX) Stock Stalls Despite Profit Surge And ORLADEYO Strength

BioCryst Pharmaceuticals (BCRX) reported a significant profit surge in Q2 2026, driven by strong ORLADEYO revenue and a European licensing deal, yet its stock remained largely unchanged. While ORLADEYO shows real patient uptake and the company has solid liquidity, concerns remain about its reliance …

BioCryst Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BCRX) 2026-08-06

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported strong Q2 results, with ORLADEYO revenue increasing 10% year-over-year and pediatric oral-pellet shipments commencing. The company maintained its 2026 ORLADEYO revenue outlook and reduced its non-GAAP operating cost guidance by ending internal drug discovery. BioCryst also completed enrollment for its …

Royal Bank Of Canada Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price

BioCryst Reports Second Quarter 2026 Financial Results

BioCryst Pharmaceuticals reported strong second-quarter 2026 financial results, with total net revenue reaching $218.3 million and ORLADEYO net revenue at $158.2 million, leading to an operating profit of $98.5 million. The company maintained its full-year ORLADEYO revenue guidance and increased total revenue guidance, while …

BioCryst Pharmaceuticals Inc (BCRX) (Q2 2026) Earnings Call Highlights: Record Revenue and ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Completed enrollment of the largest blinded hereditary angioedema (HAE) trial ever for Navenabar ahead of …

BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results

Earnings call transcript: BioCryst beats Q2 2026 estimates and lifts outlook

BioCryst Pharmaceuticals reported Q2 2026 earnings that surpassed Wall Street expectations, with adjusted earnings of $0.30 per share against an estimated $0.16, and revenue of $218.3 million compared to a forecast of $185.69 million. The company raised its full-year 2026 revenue guidance to $690 …

Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M

Earnings Call Insights: BioCryst Pharmaceuticals (BCRX) Q2 2026 MANAGEMENT VIEW * "During the second quarter, we continued to execute effectively on the commercial and development fronts. We completed the integration of Astria Therapeutics and we further increased our cash generations through growing revenue and …

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q2 Revenue $218.2M, vs. FactSet Est of $183.3M

BioCryst Pharmaceuticals, Inc. (BCRX) reported Q2 revenue of $218.2 million, significantly exceeding FactSet's estimate of $183.3 million. The company also updated its earnings guidance for the full year 2026 and announced increased Q2 earnings and revenue. Additionally, Wedbush adjusted BioCryst Pharmaceuticals' price target to …

BioCryst Starts Shipping ORLADEYO Oral Pellets to Pediatric Patients

BioCryst Pharmaceuticals reported strong Q2 2026 financial results, with total revenue up 34% year-over-year to $218.3 million and ORLADEYO revenue reaching $158.2 million. The company has begun shipping ORLADEYO oral pellets to pediatric HAE patients and raised its full-year total revenue guidance while lowering …

North Carolina pharmaceutical company laying off 47 in Hoover, leaving Birmingham area

BioCryst Pharmaceuticals, a biotechnology company based in Durham, North Carolina, is closing its Birmingham area facilities in Hoover and laying off 47 workers. This strategic move involves discontinuing internal discovery programs and shutting down its Discovery Center of Excellence, ending the company's decades-long research …

BioCryst Pharmaceuticals (BCRX) Earnings Date and Reports 2026 $BCRX

BioCryst earnings on deck: Can Orladeyo sustain momentum?

BioCryst Pharmaceuticals is set to release its second-quarter earnings, with investors focused on the revenue performance of its flagship hereditary angioedema therapy, Orladeyo. Analysts anticipate strong sequential revenue growth, and the company is undergoing a strategic transformation involving cost reductions and the integration of …